

ATTY DOCKET NO.	SERIAL NO. 09/525,998
98,385-1	1
Hauptmann et al. FILING March 15, 2000	GROUP 1646
March 15, 2000	

INFO	(Use several sheets if necess	sary)	FILING March 15, 20	100		1040		
		U.S.	. PATENT DOCUMENTS	CLASS	SUBCLASS	FILING D	OPRIATE	
NCD	DOCUMENT NUMBER	DATE	NAME	-	+			
AMINER TIAL	4,289,690	9-15-91	Pestka et al.	+++	+-+-			
EA .	4,560,649	12-24-85	Saxena et al.		++	_		
	4,560,649	12-24-85	Saxena et a.	+++	+++	+		
	4,578,335	3-25-86	Urdal et al.		++	1		
	4,609,546	9-2-86	Hiratani	-++	+++			
	4,675,285	6-23-87	Clark et al.		-+-+			
	4,789,658	12-6-88	Yoshimoto et al.	-+-+	-+-+			
	4,789,530	2-20-90	Nitecki et al.		-+-+			
	4,902,502	2-27-90	Shaw		-+			
	4,904,584	6-5-90	Katre et al.			-		
<b></b>		6-19-90	Bell et al.			<u> </u>		
4	4,935,233		FOREIGN PATENT DOCUMENTS			BCLASS	TRANS	
			COUNTRY	CL	LASS SUB	SOLAGO	YES	├-

4	4,935,233	FOREI	GN PATENT DOCUMENTS	CLASS	SUBCLASS	TRANSL YES	ATION NO
	OODUMENT NUMBER	DATE	COUNTRY	OE).iii			
	0 1 1 ma 3	-				-	
	OUT THADEHAR				-	-	-
	a IHAS			-			
	OTHER DOCK	MENTS (Includ	ding Author, Title, Date, Pertiner	nt Pages, Etc	c.)		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

6/11/02 DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not EXAMINER considered. Include copy of this form with next communication to applicant. Patent and Trademark Office \* U.S. DEPARTMENT OF COMMERCE P09C/REV03

Form PTO-A820 (also form PTO-1449)

of 17

ATTY DOCKET NO.	SERIAL NO.
98,385-B	<b>09/525,998</b>
Hauptmann et al.	GROUP 1646

	FORMATION DISCLOSURE (Use several sheets if neces	ssary)		Hauptmann et al. FILING March 15, 20	00	GRO	OUP	164	16	
		υ.5	S. PATEN	DOCUMENTS						
IINER	DOCUMENT NUMBER	DATE		NAME	CLASS	;	SUBCLA		ILING DATE FAPPROPRIA	TE
	4,966,888	10-30-90	Saxena	ı et al.						
A	5,089,261	2-18-92	Niteck	i et al.						
-	5,116,964	5-26-92	Capor	l						
-	5,136,021	8-4-92	Demb	inski et al.						
-	5,153,265	10-6-92	Shano	lle et al			-			
-	5,162,430	5-25-93	Sano	et al.			++			
	5,214,131	10-12-98		is et al.			++			
	5,252,714	10-12-93		is et al.		}-	+-1			
	5,344,915	9-6-94		aire et al. ————————————————————————————————————		-	+			
$\downarrow$	5,359,037	10-25-94		asiewicz et al.		+	+			
$\sqrt{}$	5,382,657	1-17-95		ATENT DOCUMENTS						
<del></del>		DATE		COUNTRY	Cı	LASS	SUE	BCLASS	TRANS YES	SLATION NO
	DOCUMENT NUMBER		-						ļ	
	007 2 4 2000	3					_			-
	TRADEMAN.						_		-	-
	1 RAUE								-	
	OTHER DO	CUMENTS (Inc.	luding A	uthor, Title, Date, Perti	nent Page	es, Et	(c.)			
				DATE CONSIDER	ED	, ,	/ /			
EXAMIN	NER: Initial if reference considered	-			(		<u> </u>			

(Use several sheets if necessary)

ATTY DOCKET NO.	SERIAL NO.	
98,385-В	09/525,998	
Hauptmann et al.		
FILING	GROUP	

			March 15,	2000		1646
		U.	S. PATENT DOCUMENTS			
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA	5,395,760	3-7-95	Smith et al			
	5,478,925	12-26-95	Wallach et al.			
	5,512,544	4-30-96	Wallach et al.			
	5,605,690	2-25-97	Jacobs et al.			
	5,610,279	3-11-97	Brockhaus et al.			
	5,633,145	5-27-97	Feldmann et al.			
	5,695,953	12-9-97	Wallach et al			
	5,712,155	1-27-98	Smith et al.	,		
	5,808,029	9-15-98	Brockhaus et al.			
d	5,811,261	9-22-98	Wallach et al.			
3/	5,843,791	12-1-98	Hauptmann et al.			
		FORI	EIGN PATENT DOCUMENTS		•	•
	DOCUMENT RUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	OCT 2 4 2000 S					YES NO
	OTHER DOCUM	ENTS (Includia	ng Author, Title, Date, Pertine	ent Pages, Etc.)		
EXAMINER			DATE CONSIDERED	6/11	102	
*EXAMINER: In		er or not citation i	s in conformance with MPEP 609: D	raw line through ci	tation if not in o	onformance and not

considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

ATTY DOCKET NO.	SERIAL NO.
98,385-E	09/525,998
Hauptmann et al.	

	(OSC SEVERAL SHEETS II HECE	33di <b>y</b> /	FILING March 15,		GROUP	1646
<del></del>	<del> </del>		J.S. PATENT DOCUMENTS			
*EXAMINER	DOCUMENT NUMBER	DATE	NAME	Ct ASS	SUBCLASS	FILING DATE
8A	5,863,786	1-26-99	Feldmann et al.		_	IF APPROPRIATE
	7.5		-			
	OFF					
	OCI 2 1 7000 53					
	SKELLS LEVOLUNCE					
	G BAD					
<u></u>		FOI	REIGN PATENT DOCUMENTS	<b>.</b>	. 1	<u></u>
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
EA	DE03910323A1			1	1	V
1	DE03913101.7					
	DE0920282.8					
	EP0154316A2					
V	EP0154316B1					
	OTHER DOCUM	IENTS (Includ	ling Author, Title, Date, Pertine	ent Pages, Etc.	)	
EXAMINER	SA	-	DATE CONSIDERED	6/111	0)	
EXAMINER: I	nitial if reference considered, whet	her or not citation	is in conformance with MPEP 609: D	raw line through c	itation if not in c	conformance and not

(Use several sheets if necessary)

ATTY DOCKET NO.	SERIAL NO.
98,385-E	09/525,998
Hauptmann et al.	

			FILING <b>March 15, 20</b> 0		ROUP	1646	
		U.S. 1	PATENT DOCUMENTS	<del> </del>			
'EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DAT	
	OIPE						
	2000						
	Util to the						
	SERVE MADOREST						
						,	
_							
		EOREIG	SN PATENT DOCUMENTS				
		<u> </u>		T	Ι	TRANS	I ATION
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO NO
8A	EP0162699						
	EP0225579A3						
	EP0247860A2						
-1/4	EP0259863A2						
$V \perp$	EP0308378						
	OTHER DOCUMEN	Including	Author, Title, Date, Pertinent	Pages, Etc.)			
EXAMINER	GA		DATE CONSIDERED	6/11/	1 2		
*EVAMINED: I	Initial if reference considered, whether						

(Use several sheets if necessary)

ATTY DOCKET NO.	SERIAL NO.
98,385-E	09/525,998
Hauptmann et al.	

			FILING March 15, 20		ROUP	1646	
		U.S.	PATENT DOCUMENTS	<b> </b>			
'EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DAT	
	OIPE						
	2000						
	007 24 000						
	The Theorem and the services						
						:	
			<u> </u>		110		
		50051	AND DATENT DOCUMENTO				
<u> </u>		FOREIG	GN PATENT DOCUMENTS	<u> </u>	Τ	TDANG	LATION
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS YES	NO NO
GA	EP0334165A2						
	EP0393438A2						
	EP0398327A1					<del>                                     </del>	
	EP0412486						
V	EP0417563A2						
	OTHER DOCUME	NTS (Including	Author, Title, Date, Pertinent	Pages, Etc.)			
							· · · · · · · · · · · · · · · · · · ·
EXAMINER	GN		DATE CONSIDERED	6/11	102		
*EYAMINER: Ir		er or not citation is i	n conformance with MPEP 609: Draw			onformanco	and not

Form PTO-A820 (also form PTO-1449)

considered. Include copy of this form with next communication to applicant.

P09C/REV03

Patent and Trademark Office \* U.S. DEPARTMENT OF COMMERCE

98,385-E 09/525,998	ATTY DOOKET NO	CERIAL NIO
	AȚTY DOCKET NO.	SERIAL NO.
Hountmann et al	98,385-E	09/525,998
Uauntmann at al	70,000	* * * * * * * * * * * * * * * * * * * *
	Hauptmann et al.	

(Use several sheets if necessary)		Hauptmann et al.					
			FILING March 15, 20		ROUP	1646	
		U.S. P	ATENT DOCUMENTS				
EXAMINER	DOCUMENT NUMBER	DATE	NAME	CL ASS	SUBCLASS	FILING DATE	
	(IPA						
	0, 6,						
	OCT 2 4 2000 SS						
	TRADEMAN OF						
		FOREIG	N PATENT DOCUMENTS		1		
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	ATION NO
EA	EP0418014A1						
	EP0422339		·····				
	EP0433900						
	EP0512528A2						
$V_{\perp}$	EP0526905A2						
	OTHER DOCUME	NTS (Including	Author, Title, Date, Pertiner	nt Pages, Etc.)	l		
			<del></del>		1		
EXAMINER	Si V	}	DATE CONSIDERED	6 /	11/00		
EXAMINER: I	Initial if reference considered, whether	<del></del>	conformance with MPEP 609: Dra	aw line through ci	tation if not in c	onformance	and not

considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

ATTY DOCKET NO.		SERIAL NO.
98,385	-E	09/525,998
Hauptmann et al.		

(asa savarar arracia il massassary)		FILING	[(	GROUP			
			March 15, 2			1646	
		U.S. PA	ATENT DOCUMENTS				
*EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	OFE						
	OCT 2 4 2000 85						
	The read and the second						
	- Transcore						
		FOREIGN	PATENT DOCUMENTS			<del>_</del>	
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	ATION NO
9A	GB2218101						
	GB2246569A						
	WO90/13575						
$\sqrt{}$	WO91/03553						
	WO92/01002					abstract	
	OTHER DOCUME	NTS (Including A	Author, Title, Date, Pertine	nt Pages, Etc.	)		
EXAMINER	<u> </u>		DATE CONSIDERED	6/11,	/* ~		
*EYAMINED:	nitial if reference considered, whether	or not ellette = 1= 1	popformance with MPER COC. D.	<del></del>			
	rimar ir reference considered, whethe	a or nor Grandii 15 ifi (	Johnstonance with MEEP 009; Dr	aw ine unough c	nanon ii not in C	оппоннансе	and not



(Use several sheets if necessary)

ATTY DOCKET NO. 98,385-E	SERIAL NO. 09/525,998
Hauptmann et al.	
March 15, 2000	GROUP 1646

			March 15, 200		GROUP	1646	
		U.S. PA	ATENT DOCUMENTS				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DAT	
	OIPE						
	007 2 4 2000 S						
	\2 5						
	TRADIMANA OF						
		FOREIGN	PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS YES	LATION NO
EA	WO92/07076						
	WO92/13095						
	WO92/15682						
	WO92/16221						
<b>V</b>	WO93/01474						
	OTHER DOCUMEN	ITS (Including A	uthor, Title, Date, Pertinent	Pages, Etc.,	)		
,							
EXAMINER	E/A		DATE CONSIDERED	6/11/	1 3		

(Use several sheets if necessary)

ATTY DOCKET NO.	SERIAL NO.
98,385-E	09/525,998
Hauntmann et al	
Hauptmann et al.	

(Ose several sheets if necessary)		maupimann et al.					
II.C. DAT			FILING March 15, 20	000	GROUP	1646	
		U.S. P	ATENT DOCUMENTS	<u> </u>			
*EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DAT	
	(IPA						
	06						
	OCT 2 4 2000 %						
	TRADEL PAR						
	· · · · ·						
						<u> </u>	
		FOREIGN	PATENT DOCUMENTS	<del> </del>	1	<del></del>	··-
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES YES	LATION NO
EA	WO94/06476						
	OTHER DOCUME	NTS (Including A	Author, Title, Date, Pertinen	t Pages, Etc	2.)	<del></del>	
	Anderson et al., "Quant et al., eds., 1985).	<u>itative</u> Filter Hyb <del>ri</del> d	disation," Nucleic Acid Hybrid	lization: A Pra	nctical Approac	h <b>pp.</b> 73-11	1 (Hawes
EM	Aggarwal et al., "Chara gamma-interferon," Nat	cterization of recep ure 318:665-67 (198	tors for human tumour necros 35).	is factor and t	heir regulation	by	
EXAMINER	ελΑ		DATE CONSIDERED	6/1	102		
*EXAMINER: I considered. In	nitial if reference considered, whethe clude copy of this form with next con	r or not citation is in communication to application	conformance with MPEP 609; Dra	w line through	citation if not in o	onformance	and not

Form PTO-A820 (also form PTO-1449) P09C/REV03

Patent and Trademark Office \* U.S. DEPARTMENT OF COMMERCE

Docket Number (Optional)	Application Number	
98,285-H	09/525,998	
Applicant(s) Hauptmann et al.		
Filing Date	Group Art Unit	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicant(s) Hauptmann et al.		
		Filing Date March 15, 2000	Group Art Unit	
*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author)	or, Title, Date, Pertinent Pages, Etc.)		
GAPE	Baglioni et al., "Binding of human tumor nec to growth inhibition," J. Biol. Chem. 260:133	rosis factor to high affinity receptors on 95-97 (1985).	HeLa and lymphoblastoid cells sensitiv	
OCI 2 4 20	pakouche et al., "Plasma membrane-associate s own receptor," J. Immunol. 140:1142-47 (1	ed tumor necrosis factor. A non-integra 1988).	I membrane protein possibly bound to	
EA	Beutler et al., "Passive immunization against Science 229:869-71 (1985).	cachectin/tumor necrosis factor protect	s mice from lethal effect of endotoxin,"	
EA	Binkert et al., "Cloning, sequence analysis amprotein (IGFBP-2)," EMBO J. 8:2497-502 (19	d expression of a cDNA encoding a nov 89).	el insulin-like growth factor binding	
GA .	Bowie et al., "Deciphering the message in pro (1990).	tein sequences: tolerance to amino acid	substitutions," Science 247:1306-10	
97A	Brennan et al., "Inhibitory effect of TNF alph Lancet 2:244-47 (1989).	a antibodies on synovial cell interleukii	n-1 production in rheumatoid arthritis,	
EA	Brockhaus, M. et al., Proc. Natl. Acad. Sci. US	SA 87:3127-3131 (1990)		
EA	Capaldi et al., "Changes in order of migration conditions of SDS polyacrylamide gel electrop	n of polypeptides in complex III and cyt shoresis," Biochem. Biophys. Res. Comi	ochrome C oxidase under different nun. 74:425-33 (1977)	
EA	Carlino et al., " Use of a Sensitive Receptor B Recombinant TNF	inding Assay to Discriminate Between I	ull-Length and Truncated Human	
EA	Colletti et al., "The production of tumor necre hepatic ischemia/reperfusion," Transplantation	osis factor alpha and the development o on 49:268-72 (1990)	f a pulmonary capillary injury followin	
EN7	Creasy, A. et al., Proc. Natl. Acad. Sci. USA 8	4:3293-3297 (1987)		
SA	Dayer et al., "Purification and Characterizati 113(38760n):454 (1990)	on of Human Tumor Necrosis Factor a	Inhibitor," Chemical Abstracts	

EXAMINER

EM

DATE CONSIDERED

6/11/00

(Use several sheets if necessary)

Docket Number (Optional)

98,385-E

Application Number

09/525,998

Applicant(s)

Hauptmann et al.

Filing Date

Group Art Unit

March 15, 2000

1646

\*EXAMINER INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Dembic et al., "Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences," Cytokine 2:231-37 (1990).

EA

Engelmann et al., "A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity," J. Biol. Chem. 264:11974-80 (1989).

007 2 4 7000 S

Engelmann et al., "Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity," J. Biol. (Chem. 265:14497-504 (1990).

Espevik et al., "Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor," J. Exp. Med. 171:415-26 (1990).

EA-

Evans, "The steroid and thyroid hormone receptor superfamily," Science 240:889-95 (1988).

9A

Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer," Proc. Natl. Acad. Sci. U. S. A. 85:8998-9002 (1988).

ZM.

Gatanaga et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin..., Proc. Natl. Acad. Sci. USA 87:8781-8784 (1990).

EA

Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site," BioTechnology 8:343-346 (1990).

EM

Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," Mol. Cell. Biol. 11:3020-26 (1991).

EA

Gray et al., "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein," Proc. Natl. Acad. Sci. U. S. A. 87:7380-84 (1990).

EA

Grizzard et al., "Affinity-labeled somatomedin-C receptors and binding proteins from the human fetus," J. Clin. Endocrinol. Metab. 58:535-43 (1984).

EA

Hale et al., "Cytokines and Their Receptors: From Clonal to Clinical Investigation, Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. Coli," J. Cell Biochem. Suppl. 15F:113(1991)

EXAMINER

8/X

DATE CONSIDERED

6/11/02

(Use several sheets if necessary)

Docket Number (Optional)

98,385-E

Application Number

09/525,998

Applicant(s)

Hauptmann et al.

Filing Date

March 15, 2000

Group Art Unit

1646 \*EXAMINER OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) INITIAL Hass et al., "Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibroblasts," J. Biol. Chem. 260:12214-18 (1985). Hatakeyama et al., "Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's," Science 244:551-56 (1989). Hauser et al., "Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6," Neurology 40:1735-39 (1990). Heller et al., "Amplified expression of tumor necrosis factor receptor in cells transfected with Epstein-Barr virus shuttle sector cDNA libraries," J. Biol. Chem. 265:5708-17 (1990). Himmler et al., "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein," DNA Cell Biol. 9:705-15 (1990). Hofman et al., "Tumor necrosis factor identified in multiple sclerosis brain," J. Exp. Med. 170:607-12 (1989). Israel et al. "Binding of Human TNF-alpha to High-Affinity Cell Surface Receptors: Effect of IFN," Immunol. Lett. 12:217-224(1986). Kasukabe et al., "Purification of a novel growth inhibitory factor for partially differentiated myeloid leukemic cells," J. Biol. Chem. 263:5431-35 (1988). Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor," Proc. Natl. Acad. Sci. USA 87:8331-8335 (1990). Kull et al., "Cellular receptor for 1251-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity," Proc. Natl. Acad. Sci. U. S. A. 82:5756-60 (1985). Lantz et al., "Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor," J. Clin. Invest. 86:1396-42 (1990). Le et al., "Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities," Lab. Invest. 56:234-48 (1987). EXAMINER DATE CONSIDERED 6/11/02

(Use several sheets if necessary)

Docket Number (Optional) 92,385-A

March 15, 2000

Application Number

09/525,998

Applicant(s)

Hauptmann et al.,

Filing Date

Group Art Unit

1646

\*EXAMINER INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EA

Lee et al., "Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase," Science 239:1288-91 (1988).

EM

Lehmann and Droge, "Demonstration of membrane receptors for human natural and recombinant 1251-labeled tumor necrosis factor on HeLa cell clones and their role in tumor cell sensitivity," Eur. J. Biochem. 158:1-5 (1986).

EA -

Leung et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression," Nature 330:537-43 (1987).

EM

Liao et al., "Identification of a specific interleukin 1 inhibitor in the urine of febrile patients," J. Exp. Med. 159:126-36 (1984).

017 2 4 2000 S

Liao et al., "Charaterization of a Human Interleukin 1 Inhibitor," J. Immunol. 134(6):3882-3886 (1995).

Liblau et al., "Tumor Necrosis Factor-a and Disease Progression in Multiple Sclerosis," New Engl. J. Med. 326(4):272-273 (1992)

M

Lindvall et al., "Modulation of the constitutive gene expression of the 55 kD tumor necrosis factor receptor in hematopoietic cells," Biochem. Biophys. Res. Commun. 172:557-63 (1990).

MA

Loetscher et al., "Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity," J. Biol. Chem. 266:18324-29 (1991).

EA

March et al., "Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs," Nature 315:641-47 (1985).

Neda, Hiroshi, "Analysis of the Tumor Necrosis Factor (TNF) Receptor of Various Tumor Cells," Tumor Necrosis Factor, (TNF) Receptor 56(2):305-17 (1987).

EA

Nexl et al., "Lectin-agarose immobilization, a new method for detecting soluble membrane receptors. Application to studies with epidermal growth factor-urogastrone and transcobalamin-II," J. Biol. Chem. 254:8740-43 (1979).

EA

Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA of the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," The EMBO J. 9(10):3269-3278 (1990).

EXAMINER

A DATE CONSIDERED

6/11/02

(Use several sheets if necessary)

Docket Number (Optional)

92,385-E

Application Number

09/525,998

1646

Applicant(s)

Hauptmann et al.

Filing Date

Group Art Unit

March 15, 2000

up Art Cnit

\*EXAMINER INTHAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

GA

Novick et al., "Soluble cytokine receptors are present in normal human urine," J. Exp. Med. 170:1409-14 (1989).

ENA

Novick et al., "Soluble Cytokine Receptors are Present in Normal Human Urine," The Physiological and Pathological Effects of Cytokines pp. 413-21 (1990).

EM

Novick et al., "Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography," J. Chromatogr. 510:331-37 (1990).

EN

Olsson et al., "Isolation and characterization of a tumor necrosis factor binding protein from urine," Eur. J. Haematol. 42:270-75 (1989).

PENA 2000 S

Peetre, C. et al., Eur. J. Haematol 41:414-419 (1988)

Peppel et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," J. Exp. Med. 174:1483-1489 (1991).

EA

Piguet et al., "Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis," J. Exp. Med. 170:655-63 (1989).

Powell et al., "Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity," Int. Immunol. 2:539-44 (1990).

Rhein et al., "Another Sepsis Drug Down--Immunex TNF Receptor," Biotechnology Newswatch, pg. 1,3 (Monday, October 4, 1993).

EA

Ruddle et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," J. Exp. Med. 172:1193-1200 (1990).

EA

Schall, T. J. et al., Cell 61:361-370 (1990)

EN)

Scheurich et al., "Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines," Int. J. Cancer 38:127-33 (1986).

EXAMINER

EnA

DATE CONSIDERED

6/11/0=

(Use several sheets if necessary)

Docket Number (Optional)

98,385-E

Application Number

09.525,998

Applicant(s)

Hauptmann et al.

Filing Date

15 3000

Group Art Unit

		March 15, 2000	1646
*EXAMINER INITIAL	OTHER DOCUMENTS (Includin	g Author, Title, Date, Pertinent Pages, Etc.)	
EA)	Stauber and Aggarwal, "Characterizat (tumor necrosis factor-beta) on a huma	ion and affinity cross-linking of receptors for hu in histiocytic lymphoma cell line, U-937," J. Biol	man recombinant lymphotoxin . Chem. 264:3573-76 (1989).
EA-	Suffys et al., "Involvement of a serine p 178:257-65 (1988).	protease in tumour-necrosis-factor-mediated cyto	otoxicity," Eur. J. Biochem.
EA	Suggs et al., "Use of synthetic oligonuc 2-microglobulin," Proc. Natl. Acad. Sc	leotides as hybridization probes: isolation of clor i. U. S. A. 78:6613-17 (1981).	ned cDNA sequences for human beta
ENA	The Cytokine Factsbook pp. 244-46 (C	allard, ed., Academic Press, 1994).	
WA E	(1988).	is factor induces cachexia, anemia, and inflamm	ation," J. Exp. Med. 167:1211-27
OCT 2 4 2000	Tracey et al., "Metabolic effects of cacl	nectin/tumor necrosis factor are modified by site etal muscle induces chronic cachexia, while impla h. Invest. 86:2014-24 (1990).	
ENT	Foundation Symposium 131, Wiley, Cl	to cachectin," Tumor Necrosis Factor and Relat nichester, 1987). Donoclonal Antibodies Prevent Septic Shock Durin	
	Tsujimoto et al., "Physiological respon (Clba Foundation Symposium 131), pp	ses to cachectin, "Tumor necrosis factor and rela . 88-108 (1987).	ated cytotoxins. Wiley, Chichester
SA	Unglaub et al., "Downregulation of tur protein kinase C activators," J. Exp. N	nor necrosis factor (TNF) sensitivity via modulat led. 166:1788-97 (1987).	tion of TNF binding capacity by
SA.	Vilcek et al., "Tumor necrosis factor: r	eceptor binding and mitogenic action in fibrobla	asts," J. Cell. Physiol. 5:57-61 (1987).
	Vitt et al., "Biological and Structural C Relationship to Function," Fed. Proc. 7	Characterization of the Tumor Necrosis Factor R 18th Annual Meeting of the American Society of	eceptor on Multiple Cell Types: Biological Chemists 46(6):2117 (1987)
EA	Wallach et al., "Mechanisms which tak 8:359-63 (1989).	se part in regulation of the response to tumor neo	crosis factor," Lymphokine Res.
XAMINER	EA	DATE CONSIDERED	6/11/02

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			98,385-E	09/525,998
			Applicant(s) Hauptmann et al.	
			Filing Date	Group Art Unit
			March 15, 2000	1646
*EXAMINER INTHAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
EA		Wallach, "Preparations of lymphotoxin induce resistance to their own cytotoxic effect," J. Immunol. 132:2464-69 (1984).		
-		Wallach et al., "Regulation of the Response to Tumor Necrosis Factor," pp. 134-47 (Bonavida et al., eds., Tumor Necrosis Factor/Cachectin and Related Cytokines Int. Conf. Tumor Necrosis Factor and Related Cytotoxins, Heidelberg, 1987).		
EA		Walsh et al., "Isolation and purification of ILS, an interleukin 1 inhibitor produced by human gingival epithelial cells," Clin. Exp. Immunol. 68:366-74 (1987).		
EA		Weber et al., "Production of an epidermal growth factor receptor-related protein," Science 224:294-97 (1984).		
CA	2000	Joshie et al., "Binding and Crosslinking of 1251-1 Teceptors," J. Biochem. 100:531-541 (1986).	abeled Recombinant Human Tum	or Necrosis Factor to Cell Surface
EX TO	d.Dr.svyyy	Ziegler, "Tumor necrosis factor in humans," N. E		
	i	!		
		i	<u> </u>	<u>.                                    </u>
	1			
· <u>-</u>	İ			
	<del>-</del>	<del>.</del>		
· · · ·		·		
XAMINER	•	Elec. 15.0 Naa	DATE CONSIDERED	11102

P09B/REV04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.